Cosentyx is a medication used to treat various autoimmune diseases such as psoriasis and psoriatic arthritis. According to the medication's official website [2], the dosage and frequency of Cosentyx depend on the condition being treated and the patient's medical history. For psoriasis, the recommended dose is 300 mg, administered as two subcutaneous injections of 150 mg each, at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 300 mg every 4 weeks. For psoriatic arthritis, the recommended dose is 150 mg every 4 weeks after an initial loading dose of 300 mg at weeks 0, 1, 2, 3, and 4. However, the dose and frequency of Cosentyx may vary depending on individual patient needs and response to treatment.

According to Drug Patent Watch [1], Cosentyx was first approved by the FDA in January 2015. The patent for Cosentyx is set to expire in 2032, but there may be other patents or exclusivities that affect the drug's availability.

Medical News Today [3] reports that Cosentyx is generally well-tolerated, with common side effects including upper respiratory infections, diarrhea, and reactions at the injection site. Patients should speak with their healthcare provider about any concerns or side effects they may experience while taking Cosentyx.

In summary, the frequency of Cosentyx administration depends on the condition being treated and the patient's individual needs and response to treatment. For psoriasis, the recommended dose is 300 mg every 4 weeks after an initial loading dose, while for psoriatic arthritis, the recommended dose is 150 mg every 4 weeks after an initial loading dose. Patients should speak with their healthcare provider about any concerns or side effects they may experience while taking Cosentyx.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/psoriatic-arthritis/faq
[3] https://www.medicalnewstoday.com/articles/326632